Fig. 6: seRNA treatment of glioblastoma mice.
From: Selectively expressed RNA molecules as a versatile tool for functionalized cell targeting
Tumors of human U87 glioblastoma cells were grown in immunodeficient mice and analyzed by MRI 14 days after treatment with a therapeutically inactive seRNA-eGFP construct as control (a) or the therapeutic seRNA-ca-Caspase3 construct (b). Tumor formation and mitotic activity of tumor cells were verified by Ki67 immunoreactivity (red) and nuclear staining (blue) 16 days after tumor implantation (scale bar 300 µm) (c). A zoom-in of the red dotted square is indicated below and reveals densely packed Ki67 positive tumor cells (scale bar 200 µm). Based on MRI images, tumor volumes were evaluated after treatment with control (seRNA-eGFP or NaCl) (d) or therapeutic seRNA-ca-Caspase3 constructs (e) at indicated time points. Statistical analyses were performed with repeated measures of one-way ANOVA over the factor time with p = 0.5035 for (d) and p = 0.0001 for (e). For direct comparison of control and therapeutic animals, relative tumor volumes in relation to day 3 (d3) control mice are shown. Statistical analysis was performed via one-way ANOVA over the factor time (f). For all statistical analyses box plots provide all single values for every time point. Mean values are given as the center point, the median as a line with whisker min/max values, and the s.d. as a box. Significance levels of 0.05, 0.01, and 0.001 were displayed with one to three stars. For (d–f) n = 10 for each group and time point out of 4 independent experiments.
